Effect of High-Dose vs Standard-Dose Vitamin D 3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.

التفاصيل البيبلوغرافية
العنوان:	Effect of High-Dose vs Standard-Dose Vitamin D 3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.
المؤلفون:	Brown JC; Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.; LSU Health Sciences Center, New Orleans School of Medicine, New Orleans, LA 70012, USA.; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70012, USA., Rosenthal MH; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Ma C; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Zhang S; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Nimeiri HS; Division of Hematology Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611, USA., McCleary NJ; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Abrams TA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Yurgelun MB; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Cleary JM; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Rubinson DA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Schrag D; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Bullock AJ; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Allen J; Massachusetts General Hospital, Boston, MA 02114, USA., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID 83712, USA., Chan E; Vanderbilt University Medical Center, Nashville, TN 37232, USA., Chan JA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Wolpin B; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Constantine M; Dana-Farber at Milford Regional Medical Center, Milford, MA 01757, USA., Weckstein DJ; New Hampshire Oncology Hematology, Hookset, NH 03106, USA., Faggen MA; Dana-Farber at South Shore Hospital, South Weymouth, MA 02190, USA., Thomas CA; New England Cancer Specialists, Scarborough, ME 04074, USA., Kournioti C; Newton-Wellesley Hospital, Newton, MA 02462, USA., Yuan C; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Zheng H; Massachusetts General Hospital, Boston, MA 02114, USA., Hollis BW; Department of Pediatrics, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA., Fuchs CS; Yale Cancer Center, New Haven, CT 06510, USA., Ng K; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Meyerhardt JA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
المصدر:	Cancers [Cancers (Basel)] 2020 Nov 20; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 20.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة:	Original Publication: Basel, Switzerland : MDPI
مستخلص:	Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D 3 (4000 IU) or standard-dose (400 IU) vitamin D 3 . Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D 3 , high-dose vitamin D 3 did not significantly change body weight [-0.7 kg; (95% CI: -3.5, 2.0)], body mass index [-0.2 kg/m ² ; (95% CI: -1.2, 0.7)], muscle area [-1.7 cm ² ; (95% CI: -9.6, 6.3)], muscle attenuation [-0.4 HU; (95% CI: -4.2, 3.2)], visceral adipose tissue area [-7.5 cm ² ; (95% CI: -24.5, 9.6)], or subcutaneous adipose tissue area [-8.3 cm ² ; (95% CI: -35.5, 18.9)] over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D 3 , vs standard-dose vitamin D 3 , to standard chemotherapy did not result in any changes in body composition.
References:	Br J Cancer. 2020 Oct;123(8):1205-1206. (PMID: 32624575) Endocr Rev. 2013 Feb;34(1):33-83. (PMID: 23169676) J Clin Oncol. 2007 Apr 20;25(12):1539-44. (PMID: 17442997) Diabetes. 2010 Jan;59(1):242-8. (PMID: 19833894) Clin Cancer Res. 2019 Dec 15;25(24):7497-7505. (PMID: 31548349) J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):664-672. (PMID: 29766660) Acta Physiol (Oxf). 2014 Mar;210(3):489-97. (PMID: 24393306) Br J Nutr. 2012 Dec 14;108(11):1915-23. (PMID: 23046765) Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):628-33. (PMID: 19770647) JAMA. 2019 Apr 9;321(14):1370-1379. (PMID: 30964527) Am J Clin Nutr. 2010 Oct;92(4):841-8. (PMID: 20720256) J Clin Oncol. 2011 Apr 20;29(12):1599-606. (PMID: 21422438) Am J Clin Nutr. 2015 Jul;102(1):58-65. (PMID: 26016860) BMC Med Res Methodol. 2010 Dec 31;10:112. (PMID: 21194416) Endocrinology. 1986 Nov;119(5):2214-20. (PMID: 3021437) Ann Oncol. 2019 May 1;30(5):733-743. (PMID: 30796437) Nat Rev Cancer. 2014 May;14(5):342-57. (PMID: 24705652) J Clin Oncol. 2016 Apr 20;34(12):1339-44. (PMID: 26903572) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) J Clin Endocrinol Metab. 2014 Nov;99(11):4336-45. (PMID: 25033068) Histochem J. 2001 Jan;33(1):19-24. (PMID: 11352397) BMJ. 2014 Apr 01;348:g2035. (PMID: 24690624) Stat Med. 2017 Jan 15;36(1):5-19. (PMID: 27435045) J Natl Cancer Inst. 2020 Apr 1;112(4):377-383. (PMID: 31355882) Am J Clin Nutr. 2016 Aug;104(2):454-61. (PMID: 27385610) Front Physiol. 2014 Jun 24;5:228. (PMID: 25009502) Endocr Rev. 2019 Aug 1;40(4):1109-1151. (PMID: 30321335) Nutrients. 2018 Jul 13;10(7):. (PMID: 30011816) J Biol Chem. 2006 Apr 21;281(16):11205-13. (PMID: 16467308) Obes Rev. 2014 Jun;15(6):528-37. (PMID: 24528624) Eur J Clin Nutr. 2018 Oct;72(10):1345-1357. (PMID: 29563638) PLoS One. 2012;7(12):e52171. (PMID: 23272223) J Appl Physiol (1985). 2004 Dec;97(6):2333-8. (PMID: 15310748) BMJ. 2019 Aug 12;366:l4673. (PMID: 31405892) Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2062-2069. (PMID: 31533940) J Cachexia Sarcopenia Muscle. 2018 Dec;9(7):1200-1208. (PMID: 30637983) Annu Rev Nutr. 1997;17:527-58. (PMID: 9240939) Curr Opin Clin Nutr Metab Care. 2017 May;20(3):169-174. (PMID: 28257331) J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):369-381. (PMID: 27520301) JAMA Oncol. 2019 Jul 1;5(7):967-972. (PMID: 31095251) J Clin Endocrinol Metab. 2003 Dec;88(12):5766-72. (PMID: 14671166)
معلومات مُعتمدة:	P50CA127003 United States CA NCI NIH HHS; P30-DK072476 United States DK NIDDK NIH HHS; R25-CA203650 United States CA NCI NIH HHS; P30 DK072476 United States DK NIDDK NIH HHS; R00 CA218603 United States CA NCI NIH HHS; U54 GM104940 United States GM NIGMS NIH HHS; R01 CA205406 United States CA NCI NIH HHS; R01 CA169141 United States CA NCI NIH HHS; R01CA118553 United States CA NCI NIH HHS; U54-GM104940 National Institute of General Medicine Sciences; R01CA205406 United States CA NCI NIH HHS; R00-CA218603 United States CA NCI NIH HHS; R01 CA118553 United States CA NCI NIH HHS
فهرسة مساهمة:	Keywords: adipose tissue; cholecalciferol; colorectal neoplasms; mediation; prognosis; randomized; skeletal muscle
تواريخ الأحداث:	Date Created: 20201125 Latest Revision: 20210721
رمز التحديث:	20221213
مُعرف محوري في PubMed:	PMC7699725
DOI:	10.3390/cancers12113451
PMID:	33233566
قاعدة البيانات:	MEDLINE

Find this article in full text from ProQuest

Full Text Finder

الوصف
تدمد:	2072-6694
DOI:	10.3390/cancers12113451